<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Thionamides: Side effects and toxicities</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Thionamides: Side effects and toxicities</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Thionamides: Side effects and toxicities</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 25, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Thionamide compounds were found in 1943 to inhibit thyroid hormone synthesis. They are actively transported into the thyroid gland where they inhibit both the organification of iodine to tyrosine residues in thyroglobulin and the coupling of iodotyrosines  (<a class="graphic graphic_figure graphicRef76931" href="/z/d/graphic/76931.html" rel="external">figure 1</a>) [<a href="#rid1">1</a>]. Adverse effects of thionamides include common, minor side effects (eg, rash) and rare but serious adverse effects, such as agranulocytosis and hepatotoxicity. Patients should be made aware of side effects at the time of drug initiation, preferably in writing, and at subsequent visits.</p><p>The adverse effects of <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">propylthiouracil</a> (PTU) and <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> and their management will be reviewed here. Specific issues related to their use in the treatment of Graves' disease are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PHARMACOKINETICS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">Propylthiouracil</a> (PTU) and <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> are the thionamide drugs available in the United States. Carbimazole is a third option available in many countries, but not in North America. Methimazole and carbimazole are interchangeable because carbimazole is completely metabolized to methimazole. The carbimazole dose required to yield an equivalent dose of methimazole is approximately 40 percent higher.</p><p>PTU, but not <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a>, inhibits the 5'-monodeiodinase that converts thyroxine (T4) to triiodothyronine (T3) in extrathyroidal tissue. However, methimazole has several important pharmacokinetic advantages over PTU:</p><p class="bulletIndent1"><span class="glyph">●</span>The serum half-life of <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> is four to six hours, whereas that of PTU is 75 minutes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The intrathyroidal <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> concentration, which can reach a thyroid-to-serum ratio of 100:1, remains high for up to 20 hours, considerably longer than that of PTU.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perchlorate discharge tests, which are a measure of inhibition of iodine organification, demonstrate the superiority of <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> over PTU. In one study, perchlorate discharged 37 percent of the radioiodine tracer 24 hours after a single 15 mg dose of methimazole versus only 8.6 percent after a 300 mg dose of PTU [<a href="#rid2">2</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h1">COMMON, MINOR SIDE EFFECTS</span><span class="headingEndMark"> — </span>Both <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> and <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">propylthiouracil</a> (PTU) can cause pruritus, rash, urticaria, arthralgias, arthritis, fever, abnormal taste sensation, nausea, or vomiting in up to 13 percent of patients [<a href="#rid3">3</a>]. In one trial, the percentage of patients who discontinued antithyroid drugs due to adverse reactions was 17, 29, and 34 percent for 15 or 30 mg of methimazole or PTU, respectively [<a href="#rid4">4</a>].</p><p>Mild skin reactions can be treated with antihistamine therapy without stopping <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> or PTU [<a href="#rid5">5</a>], with the caveat that some skin reactions from PTU may be indicative of vasculitis. If one drug is not tolerated, the other drug can be substituted, but up to 50 percent of patients have cross-sensitivity. For patients with serious allergic reactions, prescribing the alternative drug is not recommended and the patient should be managed with radioiodine or surgery.</p><p>The gastrointestinal side effects are dose dependent. Thus, we prefer to use divided doses in patients taking higher doses of <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> (≥20 mg) and then change to single daily dosing if tolerated and as the dose is reduced. (See  <a class="medical medical_review" href="/z/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease", section on 'Dosing'</a>.)</p><p class="headingAnchor" id="H1335728918"><span class="h1">RARE BUT SERIOUS ADVERSE EFFECTS</span></p><p class="headingAnchor" id="H2146695184"><span class="h2">Potential teratogenicity</span><span class="headingEndMark"> — </span>Thionamides have been associated with possible teratogenic effects, but teratogenic effects are more severe with <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> and carbimazole compared with <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">propylthiouracil</a> (PTU). This topic is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/7884.html" rel="external">"Hyperthyroidism during pregnancy: Treatment", section on 'Choice of thionamide'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Agranulocytosis</span><span class="headingEndMark"> — </span>Agranulocytosis is a rare but serious complication of thionamide therapy with a prevalence of 0.1 to 0.5 percent. The risk of agranulocytosis is higher for thionamides than for 20 other classes of drugs associated with this rare complication [<a href="#rid6">6</a>]. If a patient develops agranulocytosis with either PTU or <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a>, use of the other drug is contraindicated due to risk of cross-reactivity.</p><p>Agranulocytosis usually occurs within the first two to three months of treatment [<a href="#rid7">7-10</a>]. In one study from Japan, the average time to onset of agranulocytosis was 69 days (range 11 to 233 days) [<a href="#rid8">8</a>].</p><p>The risk of agranulocytosis from <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> (but not PTU) appears to be dose related. Compared with low doses of methimazole, PTU (any dose) appears more likely to cause agranulocytosis [<a href="#rid10">10</a>]. In one study, agranulocytosis was more frequent in older patients taking methimazole in doses higher than 40 mg/day [<a href="#rid11">11</a>], while in two other studies, agranulocytosis was more common with doses &gt;20 mg daily versus 5 to 15 mg daily [<a href="#rid6">6,12</a>], and in a third study, no cases were seen with methimazole doses under 30 mg and the prevalence of agranulocytosis with PTU was dose independent [<a href="#rid11">11</a>]. However, a Japanese study found that the development of agranulocytosis from methimazole was independent of dose, age, duration of treatment, or second exposure to the thionamide [<a href="#rid13">13</a>].</p><p>In the United Kingdom, reports of agranulocytosis are more common with PTU than carbimazole [<a href="#rid14">14</a>]. Most cases occur within three months after treatment is begun. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>White blood cell (WBC) assessment</strong> – It is important to obtain a complete blood count (CBC) prior to starting a thionamide since 10 percent of patients with Graves' hyperthyroidism have neutropenia (average absolute neutrophil count [ANC] 1.4±0.3 x 10<sup>9</sup>/L, which resolves with thionamide treatment [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1">We advise patients taking a thionamide to have an immediate white cell count with differential at the earliest sign of a fever, sore throat, or other infection and to discontinue the drug until the result is available.</p><p></p><p class="bulletIndent1">Controversy exists as to the value of monitoring WBC counts. Most clinicians in the United States do not perform periodic monitoring, and the American Thyroid Association (ATA) guidelines do not recommend monitoring [<a href="#rid5">5</a>]. However, a study from Japan was able to identify 78 percent of cases of granulocytopenia before the development of agranulocytosis or the onset of symptoms by checking blood counts every two weeks for the first two months of therapy [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease", section on 'Monitoring'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Recovery from agranulocytosis usually takes a few days but can be prolonged, and morbidity and death from serious infections can occur. In a Japanese registry, 30 of 754 cases (4 percent) were fatal [<a href="#rid9">9</a>]. Granulocyte colony-stimulating factor (G-CSF) has been used as adjunctive therapy in severe cases [<a href="#rid17">17</a>], but its efficacy was called into question in an older, randomized, prospective, controlled trial of 24 patients with a thionamide-induced neutrophil count of less than 500/microL, showing no difference in the time to neutrophil recovery between those who received G-CSF versus those who did not [<a href="#rid18">18</a>]. However, this study has been criticized because of its small sample size (n = 24) and the use of a likely inadequate dose of G-CSF (100 to 250 mcg/day). Subsequent nonrandomized studies have documented the effectiveness of hematopoietic growth factors to decrease the time to WBC normalization and the length of hospital stay [<a href="#rid19">19</a>]. However, there is no firm evidence that such therapy impacts mortality from antithyroid drug-induced agranulocytosis [<a href="#rid20">20</a>]. Glucocorticoid therapy is ineffective. (See  <a class="medical medical_review" href="/z/d/html/8374.html" rel="external">"Drug-induced neutropenia and agranulocytosis"</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Hepatotoxicity</span><span class="headingEndMark"> — </span>Hepatotoxicity is a rare complication of thionamide therapy. However, PTU can cause fulminant hepatic necrosis [<a href="#rid21">21,22</a>]. Over the past 20 years, 22 cases of severe hepatotoxicity in adults in the United States resulted in nine deaths and five liver transplants. Over the same period, 12 children developed liver failure, resulting in three deaths and six liver transplants. It was estimated that this complication occurs in 1 in 10,000 adults taking PTU, with an even greater risk in children (1 in 2000) [<a href="#rid21">21,23,24</a>]. PTU-related hepatotoxicity typically occurs within 90 days of starting the medication (although cases occurring up to one year have been reported), and it is not dose related. Accumulating evidence on PTU-associated hepatotoxicity, particularly in children [<a href="#rid23">23</a>], led to changes in recommendations for the use of thionamides. At a 2009 joint meeting of the ATA and US Food and Drug Administration (FDA), it was recommended that PTU <strong>not</strong> be prescribed as a first-line drug in children or adults [<a href="#rid21">21,24</a>]. PTU has a "boxed warning" because of the risk of liver failure. (See  <a class="medical medical_review" href="/z/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease", section on 'Choice of drug'</a>.)</p><p>It is important to measure liver function tests prior to starting a thionamide since hyperthyroidism per se can cause elevations in transaminases and alkaline phosphatase. In a meta-analysis, elevations in alanine aminotransferase (ALT), aspartate transaminase (AST), and alkaline phosphatase were seen in 33, 23, and 44 percent of hyperthyroid patients, respectively, and became normal after thionamide therapy in 83, 87, and 57 percent of patients [<a href="#rid25">25</a>]. Importantly, elevations in alkaline phosphatase may originate from bone.</p><p>Patients taking PTU or <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> who develop jaundice, dark urine, light stools, abdominal pain, anorexia, nausea, or other evidence of hepatic dysfunction should be told to discontinue the drug immediately and to contact the clinician for assessment of liver function (transaminases, bilirubin) [<a href="#rid5">5</a>]. PTU should not be used if transaminases reach three times the upper limit of normal and fail to improve on repeat testing one week later. After discontinuation, liver function tests should be monitored weekly until normalization. If they do not normalize, immediate referral to a hepatologist or gastroenterologist may be necessary.</p><p>Serum transaminase concentrations increase transiently in up to one-third of patients taking PTU; this abnormality may be associated with focal hepatic necrosis on liver biopsy [<a href="#rid26">26</a>]. A literature survey published in 1997 reported 49 cases of hepatotoxicity, 28 associated with PTU (including seven deaths) and 21 associated with <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> (including three deaths) [<a href="#rid27">27</a>]. There was no relationship between a fatal outcome and either the dose or duration of thionamide treatment.</p><p>Although <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> has been associated with liver disease, reports from the United States had suggested it is typically due to cholestatic dysfunction not hepatocellular inflammation [<a href="#rid28">28</a>]. In contrast, studies from Taiwan and China suggest similar [<a href="#rid29">29</a>] or higher rates of hepatitis with methimazole than PTU when the dose exceeded 13 mg/day [<a href="#rid30">30</a>], although the risk of liver failure was less [<a href="#rid30">30</a>]; almost all cases occurred within the first 180 days of treatment [<a href="#rid30">30</a>]. In Japan, among 18,558 patients with newly diagnosed Graves' disease, severe drug-induced liver injury (ALT higher than 20 times, or total bilirubin higher than 10 times the upper limit of normal) was 0.68 percent for PTU and 0.08 percent for methimazole, with no fatalities [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H2303719009"><span class="h2">ANCA-positive vasculitis</span><span class="headingEndMark"> — </span>An antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis has been reported in association with PTU use [<a href="#rid32">32</a>]. There is also a possible association between <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> and ANCA-positive vasculitis, but the number of cases is too small to establish a cause-and-effect relationship. This is one of several reasons why we strongly prefer the use of methimazole or carbimazole rather than PTU.</p><p>In a review of studies of patients with thionamide-induced ANCA-positive vasculitis, ANCA were present in 4 to 64 percent of patients taking PTU and 0 to 16 percent of patients taking <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a>; however, only approximately 15 percent (1 in 6) of ANCA-positive patients develop clinical evidence of vasculitis [<a href="#rid32">32</a>]. In a subsequent prospective study from Brazil, 21 percent of patients taking methimazole had ANCA, but none developed vasculitis [<a href="#rid33">33</a>]. Approximately one-third of the studies showed an association between duration of thionamide therapy and onset of ANCA positivity. In a retrospective report of 16 cases from China, median time of onset of PTU-induced ANCA-associated vasculitis was 36 months (range 1 to 193 months) [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">"Clinical spectrum of antineutrophil cytoplasmic autoantibodies", section on 'Drug-induced ANCA-associated vasculitis'</a>.)</p><p>Clinical symptoms of ANCA-positive vasculitis may include fever; joint pain; weight loss; myalgia; ocular signs (eg, uveitis, scleritis); painful, necrotic, purpuric skin lesions, often affecting the ears and nose; hematuria, reflecting glomerular injury; hemoptysis; and central nervous system involvement. Since the majority of ANCA-positive patients have no clinical symptoms of vasculitis, we only assess ANCA levels in those patients who have symptoms consistent with possible vasculitis.</p><p>Treatment involves discontinuation of the offending drug and immunosuppressive therapy with glucocorticoids and other agents like <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>. (See  <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Drug-induced ANCA-associated vasculitis'</a>.)</p><p class="headingAnchor" id="H90897702"><span class="h2">Pancreatitis</span><span class="headingEndMark"> — </span>In 2019, the European Medicines Agency (but not the FDA) added pancreatitis to the potential adverse reactions related to treatment with <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> based on six case reports [<a href="#rid35">35,36</a>]. A registry-based study from Denmark identified 119,697 patients exposed to antithyroid drugs between 1995 and 2018. Excluding alcohol and gallstone-related pancreatitis, 459 were admitted to the hospital with a first case of pancreatitis (odds ratio [OR] 1.56 [95% CI 1.04-2.33]) for methimazole (n = 400) and 0.88 (95% CI 0.26-2.96) for PTU (n = 59) [<a href="#rid37">37</a>]. In another study (n = 23,807), the relative risk of pancreatitis was 3.4 (95% CI 2.12-5.48), 2.4 (95% CI 1.36-4.23), and 2.8 (95% CI 1.66-4.73), in the first, second, and third nine-month intervals after initiation of treatment, and fell to nonsignificant levels thereafter [<a href="#rid38">38</a>]. The absolute risk was 0.4 percent. Patients should be informed of this rare serious side effect of methimazole.</p><p class="headingAnchor" id="H92678192"><span class="h2">Other</span><span class="headingEndMark"> — </span>Other rare but serious side effects of thionamides include aplastic anemia [<a href="#rid39">39</a>] and insulin autoimmune syndrome with hypoglycemia (<a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a>) [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H10502512"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109107.html" rel="external">"Society guideline links: Hyperthyroidism"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15437.html" rel="external">"Patient education: Hyperthyroidism (overactive thyroid) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2178.html" rel="external">"Patient education: Hyperthyroidism (overactive thyroid) (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/2168.html" rel="external">"Patient education: Antithyroid drugs (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thionamides</strong> – <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">Propylthiouracil</a> (PTU) and <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> are the thionamide drugs available in the United States. Carbimazole is a third option available in many countries, but not in North America. Methimazole and carbimazole are interchangeable because carbimazole is completely metabolized to methimazole. The carbimazole dose required to yield an equivalent dose of methimazole is approximately 40 percent higher. (See <a class="local">'Pharmacokinetics'</a> above.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">Methimazole</a> has clinical advantages and less severe toxicity when compared with PTU, and it is usually preferred to PTU (except during the first trimester of pregnancy or during the initial treatment of thyroid storm). (See  <a class="medical medical_review" href="/z/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease", section on 'Choice of drug'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common minor side effects</strong> – Both <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> and PTU can cause pruritus, rash, urticaria, arthralgias, arthritis, fever, abnormal taste sensation, nausea, or vomiting in up to 13 percent of patients [<a href="#rid3">3</a>]. (See <a class="local">'Common, minor side effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rare but serious side effects</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Agranulocytosis</strong> – Agranulocytosis is a rare but serious complication of thionamide therapy, with a prevalence of 0.1 to 0.5 percent. (See <a class="local">'Agranulocytosis'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>It is important to obtain a complete blood count (CBC) prior to starting a thionamide since 10 percent of patients with Graves' hyperthyroidism have neutropenia, which resolves with thionamide treatment.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We advise patients taking a thionamide to have a white blood cell (WBC) count with differential at the earliest sign of a fever, sore throat, or other infection and to discontinue the drug until the result is available.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hepatotoxicity</strong> – Hepatotoxicity is a rare complication of thionamide therapy. PTU can cause fulminant hepatic necrosis. Although hepatocellular inflammation has also been reported with <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a>, severe drug-induced liver injury occurs less frequently than with PTU. (See <a class="local">'Hepatotoxicity'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>It is important to measure liver function tests prior to starting a thionamide since hyperthyroidism itself can cause elevations in transaminases and alkaline phosphatase, which normalize in the majority of patients with thionamide treatment.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients taking PTU or <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> who develop jaundice, dark urine, light stools, or other evidence of hepatic dysfunction should be told to discontinue the drug immediately and to contact the clinician for assessment of liver function.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cooper DS. Antithyroid drugs. N Engl J Med 2005; 352:905.</a></li><li><a class="nounderline abstract_t">Okamura K, Ikenoue H, Shiroozu A, et al. Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 1987; 65:719.</a></li><li><a class="nounderline abstract_t">Sundaresh V, Brito JP, Wang Z, et al. Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2013; 98:3671.</a></li><li><a class="nounderline abstract_t">Otsuka F, Noh JY, Chino T, et al. Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Clin Endocrinol (Oxf) 2012; 77:310.</a></li><li><a class="nounderline abstract_t">Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26:1343.</a></li><li><a class="nounderline abstract_t">van Staa TP, Boulton F, Cooper C, et al. Neutropenia and agranulocytosis in England and Wales: incidence and risk factors. Am J Hematol 2003; 72:248.</a></li><li><a class="nounderline abstract_t">Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2007; 146:657.</a></li><li><a class="nounderline abstract_t">Watanabe N, Narimatsu H, Noh JY, et al. Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves' disease. J Clin Endocrinol Metab 2012; 97:E49.</a></li><li><a class="nounderline abstract_t">Nakamura H, Miyauchi A, Miyawaki N, Imagawa J. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab 2013; 98:4776.</a></li><li><a class="nounderline abstract_t">Andersen SL, Olsen J, Laurberg P. Antithyroid Drug Side Effects in the Population and in Pregnancy. J Clin Endocrinol Metab 2016; 101:1606.</a></li><li><a class="nounderline abstract_t">Cooper DS, Goldminz D, Levin AA, et al. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med 1983; 98:26.</a></li><li><a class="nounderline abstract_t">Takata K, Kubota S, Fukata S, et al. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 2009; 19:559.</a></li><li><a class="nounderline abstract_t">Tamai H, Takaichi Y, Morita T, et al. Methimazole-induced agranulocytosis in Japanese patients with Graves' disease. Clin Endocrinol (Oxf) 1989; 30:525.</a></li><li><a class="nounderline abstract_t">Pearce SH. Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin Endocrinol (Oxf) 2004; 61:589.</a></li><li><a class="nounderline abstract_t">Scappaticcio L, Maiorino MI, Maio A, et al. Neutropenia in patients with hyperthyroidism: Systematic review and meta-analysis. Clin Endocrinol (Oxf) 2021; 94:473.</a></li><li><a class="nounderline abstract_t">Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med 1990; 150:621.</a></li><li><a class="nounderline abstract_t">Balkin MS, Buchholtz M, Ortiz J, Green AJ. Propylthiouracil (PTU)-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF). Thyroid 1993; 3:305.</a></li><li><a class="nounderline abstract_t">Fukata S, Kuma K, Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Thyroid 1999; 9:29.</a></li><li><a class="nounderline abstract_t">Andrès E, Kurtz JE, Perrin AE, et al. Haematopoietic growth factor in antithyroid-drug-induced agranulocytosis. QJM 2001; 94:423.</a></li><li><a class="nounderline abstract_t">Andrès E, Zimmer J, Mecili M, et al. Clinical presentation and management of drug-induced agranulocytosis. Expert Rev Hematol 2011; 4:143.</a></li><li><a class="nounderline abstract_t">Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab 2009; 94:1881.</a></li><li class="breakAll">FDA Drug Safety Communication: New Boxed Warning on severe liver injury with propylthiouracil, April 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm209023.htm (Accessed on April 22, 2010).</li><li><a class="nounderline abstract_t">Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab 2010; 95:3260.</a></li><li><a class="nounderline abstract_t">Bahn RS, Burch HS, Cooper DS, et al. The Role of Propylthiouracil in the Management of Graves' Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 2009; 19:673.</a></li><li><a class="nounderline abstract_t">Scappaticcio L, Longo M, Maiorino MI, et al. Abnormal Liver Blood Tests in Patients with Hyperthyroidism: Systematic Review and Meta-Analysis. Thyroid 2021; 31:884.</a></li><li><a class="nounderline abstract_t">Liaw YF, Huang MJ, Fan KD, et al. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. Ann Intern Med 1993; 118:424.</a></li><li><a class="nounderline abstract_t">Williams KV, Nayak S, Becker D, et al. Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? J Clin Endocrinol Metab 1997; 82:1727.</a></li><li><a class="nounderline abstract_t">Arab DM, Malatjalian DA, Rittmaster RS. Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole. J Clin Endocrinol Metab 1995; 80:1083.</a></li><li><a class="nounderline abstract_t">Yang J, Li LF, Xu Q, et al. Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China. Thyroid 2015; 25:278.</a></li><li><a class="nounderline abstract_t">Wang MT, Lee WJ, Huang TY, et al. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J Clin Pharmacol 2014; 78:619.</a></li><li><a class="nounderline abstract_t">Suzuki N, Noh JY, Hiruma M, et al. Analysis of Antithyroid Drug-Induced Severe Liver Injury in 18,558 Newly Diagnosed Patients with Graves' Disease in Japan. Thyroid 2019; 29:1390.</a></li><li><a class="nounderline abstract_t">Balavoine AS, Glinoer D, Dubucquoi S, Wémeau JL. Antineutrophil Cytoplasmic Antibody-Positive Small-Vessel Vasculitis Associated with Antithyroid Drug Therapy: How Significant Is the Clinical Problem? Thyroid 2015; 25:1273.</a></li><li><a class="nounderline abstract_t">Andrade GC, Maia FCP, Mourão GF, et al. Antineutrophil cytoplasmic antibodies in patients treated with methimazole: a prospective Brazilian study. Braz J Otorhinolaryngol 2019; 85:636.</a></li><li><a class="nounderline abstract_t">Yang J, Yao LP, Dong MJ, et al. Clinical Characteristics and Outcomes of Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Patients with Graves' Disease: A Median 38-Month Retrospective Cohort Study from a Single Institution in China. Thyroid 2017; 27:1469.</a></li><li><a class="nounderline abstract_t">Yang M, Qu H, Deng HC. Acute pancreatitis induced by methimazole in a patient with Graves' disease. Thyroid 2012; 22:94.</a></li><li><a class="nounderline abstract_t">Agito K, Manni A. Acute Pancreatitis Induced by Methimazole in a Patient With Subclinical Hyperthyroidism. J Investig Med High Impact Case Rep 2015; 3:2324709615592229.</a></li><li><a class="nounderline abstract_t">Brix TH, Lund LC, Henriksen DP, et al. Methimazole and risk of acute pancreatitis. Lancet Diabetes Endocrinol 2020; 8:187.</a></li><li><a class="nounderline abstract_t">Pecere A, Caputo M, Sarro A, et al. Methimazole Treatment and Risk of Acute Pancreatitis: A Population-based Cohort Study. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Thomas D, Moisidis A, Tsiakalos A, et al. Antithyroid drug-induced aplastic anemia. Thyroid 2008; 18:1043.</a></li><li><a class="nounderline abstract_t">Roh E, Kim YA, Ku EJ, et al. Two cases of methimazole-induced insulin autoimmune syndrome in graves' disease. Endocrinol Metab (Seoul) 2013; 28:55.</a></li></ol></div><div id="topicVersionRevision">Topic 7875 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15745981" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Antithyroid drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3654917" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23824415" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22332800" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hepatotoxicity and cutaneous reactions after antithyroid drug administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27521067" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12666135" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Neutropenia and agranulocytosis in England and Wales: incidence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470834" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Systematic review: agranulocytosis induced by nonchemotherapy drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22049174" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24057289" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26815881" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Antithyroid Drug Side Effects in the Population and in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6687345" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19445623" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2605789" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Methimazole-induced agranulocytosis in Japanese patients with Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15521961" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32799342" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Neutropenia in patients with hyperthyroidism: Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2310281" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7509672" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Propylthiouracil (PTU)-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10037073" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11493719" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Haematopoietic growth factor in antithyroid-drug-induced agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21495924" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical presentation and management of drug-induced agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19401361" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Putting propylthiouracil in perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19401361" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Putting propylthiouracil in perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20427502" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19583480" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The Role of Propylthiouracil in the Management of Graves' Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33327837" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Abnormal Liver Blood Tests in Patients with Hyperthyroidism: Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8439116" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9177371" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7714072" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25384184" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25279406" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31573408" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Analysis of Antithyroid Drug-Induced Severe Liver Injury in 18,558 Newly Diagnosed Patients with Graves' Disease in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26414658" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Antineutrophil Cytoplasmic Antibody-Positive Small-Vessel Vasculitis Associated with Antithyroid Drug Therapy: How Significant Is the Clinical Problem?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30057255" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Antineutrophil cytoplasmic antibodies in patients treated with methimazole: a prospective Brazilian study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29088997" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical Characteristics and Outcomes of Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Patients with Graves' Disease: A Median 38-Month Retrospective Cohort Study from a Single Institution in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22136208" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Acute pancreatitis induced by methimazole in a patient with Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26425645" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Acute Pancreatitis Induced by Methimazole in a Patient With Subclinical Hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32035032" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Methimazole and risk of acute pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32813014" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Methimazole Treatment and Risk of Acute Pancreatitis: A Population-based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18816182" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Antithyroid drug-induced aplastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24396652" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Two cases of methimazole-induced insulin autoimmune syndrome in graves' disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
